1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Mesa Royalty Trust announced that no distribution will be paid for September 2026 because costs, charges and expenses tied to its royalty properties exceeded the revenue received from hydrocarbon sales, as reported by the working interest owners. The filing also states that distributions are expected to be materially reduced until the Trust builds cash reserves to $2.0 million, and that accumulated excess production costs may result in no distributions in some periods.
No distribution will be paid for September 2026.
Costs and expenses attributable to the royalty properties exceeded revenue from hydrocarbon sales, as reported by working interest owners.
Distributions are expected to be materially reduced until the Trust's cash reserves reach $2.0 million.
Accumulated excess production costs will decrease distributions and may result in no distributions in some periods.
Progressive reported August 2026 results in a news release furnished under Regulation FD. Net premiums written rose 6% to $7,605 million, but net income fell 22% to $951 million and diluted earnings per share fell 21% to $1.63, with the combined ratio rising to 89.3 from 83.1. Shareholders see higher premium volume alongside lower monthly profit, driven by a higher loss and expense ratio.
Net income was $951 million versus $1,220 million in August 2025, down 22%.
Diluted earnings per share were $1.63 versus $2.07 a year earlier, down 21%.
Net premiums written rose 6% to $7,605 million; policies in force reached 40,492 thousand, up 7%.
Companywide combined ratio was 89.3 versus 83.1, with catastrophe losses from severe weather cited for the month.
BlossomHill Therapeutics reported a second-quarter 2026 net loss of $23.8 million, or $(8.75) per share, up from $13.2 million, or $(5.51) per share, a year earlier, as research and development and general and administrative expenses rose. The company said its August 2026 initial public offering brought in $168.3 million in gross proceeds, and that it expects its cash and IPO proceeds to fund operations into the second quarter of 2028.
Q2 2026 net loss was $23.8 million, or $(8.75) per share, versus $13.2 million, or $(5.51) per share, in Q2 2025.
R&D expenses rose to $21.4 million from $12.5 million; G&A expenses rose to $3.3 million from $1.6 million.
Cash and cash equivalents were $95.4 million at June 30, 2026; the August 2026 IPO sold 10,516,240 shares for $168.3 million gross.
The FDA granted Fast Track designation to BH-30643 for advanced EGFR C797S-positive NSCLC; an end-of-phase 1 meeting is planned for Q4 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.